DUBLIN – Galapagos NV is in line for a $200 million payday, as positive 24-week data from a phase IIb monotherapy trial in rheumatoid arthritis (RA) testing selective Janus kinase 1 (JAK1) inhibitor filgotinib (GLPG0634) completed the clinical picture and formally set the clock ticking on Abbvie Inc.'s option on the program.